Yi-Xin Zhang1, Zhuo-Zhi Liang2,3, Yun-Qian Li1, Ying Lin4, Qiang Liu3, Xiao-Ming Xie5, Lu-Ying Tang6, Ze-Fang Ren7. 1. School of Public Health, Sun Yat-sen University, 74 Zhongshan 2nd Rd, Guangzhou, 510080, China. 2. School of Basic Medical Science, Southern Medical University, Guangzhou, China. 3. Breast Tumor Center, Second Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. 4. The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China. 5. Department of Breast Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. 6. The Third Affiliated Hospital, Sun Yat-sen University, 600 Tianhe Rd, Guangzhou, 510630, China. tangly@mail.sysu.edu.cn. 7. School of Public Health, Sun Yat-sen University, 74 Zhongshan 2nd Rd, Guangzhou, 510080, China. renzef@mail.sysu.edu.cn.
Abstract
PURPOSE: Results of the associations between weight change after breast cancer diagnosis and prognosis were inconsistent. The modification effects of menopausal status and endocrine therapy on the associations remain poorly understood. METHODS: A total of 2016 breast cancer patients were recruited between October 2008 and January 2018 and followed up until December 31, 2019 in Guangzhou. Multivariate Cox models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (95% CIs) for progression-free survival (PFS) in association with weight change after diagnosis. RESULTS: Weight loss at 2 years (HR = 1.34, 95% CI 0.87-2.06) or more than 2 years (HR = 1.95, 95% CI 1.22-3.10) after diagnosis increased risk of breast cancer progression. The adverse effect of weight loss was significantly more pronounced in post-menopausal than pre-menopausal women, particularly for weight loss at 2 years after diagnosis, with the HRs and 95% CIs of 2.41 (1.25-4.63) and 0.90 (0.49-1.64), respectively. Weight gain tended to reduce the risk of disease progression among patients with endocrine therapy but not for those with non-endocrine therapy; the significant interaction between weight gain at 2 years after diagnosis and endocrine therapy was observed (Pinteraction = 0.042). CONCLUSION: Our finding suggested that weight loss was detrimental to breast cancer prognosis, particularly for post-menopausal women, while weight gain may be a potential beneficial indicator for the patients with endocrine therapy but not for those with non-endocrine therapy.
PURPOSE: Results of the associations between weight change after breast cancer diagnosis and prognosis were inconsistent. The modification effects of menopausal status and endocrine therapy on the associations remain poorly understood. METHODS: A total of 2016 breast cancer patients were recruited between October 2008 and January 2018 and followed up until December 31, 2019 in Guangzhou. Multivariate Cox models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (95% CIs) for progression-free survival (PFS) in association with weight change after diagnosis. RESULTS: Weight loss at 2 years (HR = 1.34, 95% CI 0.87-2.06) or more than 2 years (HR = 1.95, 95% CI 1.22-3.10) after diagnosis increased risk of breast cancer progression. The adverse effect of weight loss was significantly more pronounced in post-menopausal than pre-menopausal women, particularly for weight loss at 2 years after diagnosis, with the HRs and 95% CIs of 2.41 (1.25-4.63) and 0.90 (0.49-1.64), respectively. Weight gain tended to reduce the risk of disease progression among patients with endocrine therapy but not for those with non-endocrine therapy; the significant interaction between weight gain at 2 years after diagnosis and endocrine therapy was observed (Pinteraction = 0.042). CONCLUSION: Our finding suggested that weight loss was detrimental to breast cancer prognosis, particularly for post-menopausal women, while weight gain may be a potential beneficial indicator for the patients with endocrine therapy but not for those with non-endocrine therapy.
Authors: Patrick T Bradshaw; Joseph G Ibrahim; June Stevens; Rebecca Cleveland; Page E Abrahamson; Jessie A Satia; Susan L Teitelbaum; Alfred I Neugut; Marilie D Gammon Journal: Epidemiology Date: 2012-03 Impact factor: 4.822
Authors: Dirk De Ruysscher; Gabriele Niedermann; Neil G Burnet; Shankar Siva; Anne W M Lee; Fiona Hegi-Johnson Journal: Nat Rev Dis Primers Date: 2019-02-21 Impact factor: 52.329
Authors: Xiaoli Chen; Wei Lu; Wei Zheng; Kai Gu; Zhi Chen; Ying Zheng; Xiao Ou Shu Journal: Breast Cancer Res Treat Date: 2010-01-08 Impact factor: 4.872
Authors: Bette J Caan; Marilyn L Kwan; Georgina Hartzell; Adrienne Castillo; Martha L Slattery; Barbara Sternfeld; Erin Weltzien Journal: Cancer Causes Control Date: 2008-08-28 Impact factor: 2.506
Authors: D S M Chan; A R Vieira; D Aune; E V Bandera; D C Greenwood; A McTiernan; D Navarro Rosenblatt; I Thune; R Vieira; T Norat Journal: Ann Oncol Date: 2014-04-27 Impact factor: 32.976